At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AEMD Aethlon Medical
Trading 06-30 10:36:52 EDT
0.8250
-0.0233
-2.75%
High0.8668Low0.8249Vol91.89K
Open0.8500D1 Closing0.8483Amplitude4.94%
Mkt Cap1.96MTradable Cap1.88MTotal Shares2.37M
T/O78.10KT/O Rate4.03%Tradable Shares2.28M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aethlon Medical announces publication demonstrating potential of Hemopurifier
TIPRANKS  ·  06-26
Aethlon Medical announces publication demonstrating potential of Hemopurifier
Aethlon Medical Study Flags Long COVID Biomarker, Supports Hemopurifier Evaluation
Reuters  ·  06-26
Aethlon Medical Study Flags Long COVID Biomarker, Supports Hemopurifier Evaluation
Aethlon Medical posts corporate presentation on Hemopurifier blood-filtration platform targeting cancer, viral threats, transplant
Reuters  ·  06-18
Aethlon Medical posts corporate presentation on Hemopurifier blood-filtration platform targeting cancer, viral threats, transplant
Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD), Johnson & Johnson (JNJ) and Phreesia (PHR)
TIPRANKS  ·  06-12
Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD), Johnson & Johnson (JNJ) and Phreesia (PHR)
Aethlon Medical posts corporate presentation on Hemopurifier platform targeting cancer, viral threats, transplant
Reuters  ·  06-12
Aethlon Medical posts corporate presentation on Hemopurifier platform targeting cancer, viral threats, transplant
Aethlon Medical Reports Fiscal 2026 Results, Clinical Progress
TIPRANKS  ·  06-11
Aethlon Medical Reports Fiscal 2026 Results, Clinical Progress
Aethlon Medical Q4 EPS $0.40 Beats $(2.02) Estimate
Benzinga  ·  06-11
Aethlon Medical Q4 EPS $0.40 Beats $(2.02) Estimate
Aethlon Medical FY26 net loss narrows 46.58% to $7.2 million
Reuters  ·  06-11
Aethlon Medical FY26 net loss narrows 46.58% to $7.2 million
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
THOMSON REUTERS  ·  06-11
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  06-10
Calendar of U.S. Earnings Expected in the Week Ahead
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  06-08
Calendar of U.S. Earnings Expected in the Week Ahead
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  06-05
Calendar of U.S. Earnings Expected in the Week Ahead
Aethlon Medical updates ATM program, authorizes up to $542,716 in additional common stock sales
Reuters  ·  06-04
Aethlon Medical updates ATM program, authorizes up to $542,716 in additional common stock sales
Aethlon Medical to release fiscal year-end results, host conference call
Reuters  ·  06-02
Aethlon Medical to release fiscal year-end results, host conference call
Aethlon Medical Inc: Hemopurifier, Though Investigational, Showed Rapid Viral Reduction in One Ebola Patient in Germany
THOMSON REUTERS  ·  05-21
Aethlon Medical Inc: Hemopurifier, Though Investigational, Showed Rapid Viral Reduction in One Ebola Patient in Germany
Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
THOMSON REUTERS  ·  05-21
Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025
Reuters  ·  03-28
Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025
Aethlon Medical advances to final cohort in AEMD-2022-06 trial
TIPRANKS  ·  03-24
Aethlon Medical advances to final cohort in AEMD-2022-06 trial
Aethlon Medical opens final cohort in Hemopurifier oncology trial after DSMB review finds no safety concerns
Reuters  ·  03-24
Aethlon Medical opens final cohort in Hemopurifier oncology trial after DSMB review finds no safety concerns
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive Dsmb Review
THOMSON REUTERS  ·  03-24
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive Dsmb Review

Introduction

Company Name.
Aethlon Medical
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
Issue price:
--